Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL) last released its earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Stock Up 0.8 %

Shares of CADL stock opened at $4.80 on Friday. Candel Therapeutics has a 12 month low of $3.79 and a 12 month high of $14.60. The firm has a market cap of $236.50 million, a PE ratio of -2.77 and a beta of -0.92. The stock has a 50 day moving average of $6.04 and a 200-day moving average of $6.67.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 31,278 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.82, for a total value of $275,871.96. Following the sale, the chief technology officer now directly owns 85,512 shares in the company, valued at $754,215.84. This represents a 26.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Charles Schoch sold 5,000 shares of Candel Therapeutics stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.83, for a total value of $44,150.00. Following the transaction, the insider now directly owns 38,038 shares of the company’s stock, valued at approximately $335,875.54. The trade was a 11.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 41.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Candel Therapeutics in a research report on Friday, April 11th. Citigroup started coverage on Candel Therapeutics in a research note on Thursday, February 20th. They set a “buy” rating and a $25.00 price target on the stock. Bank of America assumed coverage on Candel Therapeutics in a report on Friday, February 7th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group boosted their price objective on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.